Clinical Pathways Congress

09/06/17


September 8-10 marks the second annual Clinical Pathways Congress. Leading experts in pathway development, implementation, and evaluation will convene in Washington, DC to discuss these and other hot topics related to oncology clinical pathways. Individuals such as Gary H Lyman, MD, MPH, Hutchinson Cancer Research Center, University of Washington, and Robert Daly, MD, Memorial Sloan Kettering Cancer Center, will provide essential tips and ideas about how to ensure that pathways are meeting the needs of patients, providers, and payers.

The meeting will feature sessions from prominent names in clinical pathways and oncology, including a keynote breast cancer clinical pathway committee development meeting headed by Bruce Feinberg, DO, Cardinal Health Specialty Solutions, a discussion on emerging treatments and pathways for the management of chronic lymphocytic leukemia led by Jennifer R Brown, MD, PhD, Dana-Farber Cancer Institute, and some pointers on the future direction of American Society of Clinical Oncology's (ASCO) policy on clinical pathways from Dr Daly and Robin T Zon, MD, FACP, FASCO, chair of the ASCO pathways taskforce.

Stay up-to-date on the latest live coverage of the most important sessions and happenings at this year's Clinical Pathways Congress.
Clinical pathway development needs to better take into account the patient perspective of cancer care, according to Alan Balch, PhD, in a presentation at the Clinical Pathways Congress. | Read More
Approximately 170 million covered lives in oncology are potentially impacted by clinical pathways, representing 57% of the patient population. The American Society of Clinical Oncology (ASCO) has taken notice, and has actively participated in the conversation surrounding clinical pathways. | Read More
Biosimilars occupy a huge place in the oncology treatment conversation these days. But what are they exactly, and how will they impact clinical pathways? | Read More
Jennifer R Brown, MD, PhD, presented the emerging treatments and management options for front line and relapsed or refractory chronic lymphocytic leukemia today at the Clinical Pathways Congress. | Read More

Pharmaceutical manufacturers can serve as a valuable resource to clinical pathway developers and decision-makers by providing relevant medical information about their products to be incorporated into evidence reviews.

| Read More
On Saturday morning at 8:00 am, all eyes at the Clinical Pathways Congress will be on the Breast Cancer Clinical Pathway Committee Development Meeting. | Read More
This year’s Clinical Pathways Congress will take place in Washington, DC, from September 8–10, and promises to include a wide array of topics representing up-to-the-minute advancements in the field. | Read More